Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Start-Up Quarterly Statistics, Q3 2014

This article was originally published in Start Up

Executive Summary

Start-ups raised $1.19 billion in Q3 2014, 33% more than last quarter. Several reverse licensing alliances were penned; five acquisitions were signed, four in biopharma and one in the device sector.

You may also be interested in...



Cancer Immunotherapy Reaches A Tipping Point

Now that it is clear the immune system can kill cancer, all kinds of companies are obsessed with the idea. Start-ups are tailoring business models to divergent technologies and market dynamics.

GSK’s Venture Deal With Avalon Yields Three Start-Ups In Two Years

Silarus Therapeutics and Thyritope Biosciences are the latest two companies to be launched and financed by GlaxoSmithKline and partner Avalon Ventures. During Informa’s Pharmaceutical Strategy Conference, GSK’s Lon Cardon talks about how the partnership with Avalon is helping the Big Pharma access academic science.

Infinity Gets More Than A Cash Boost With AbbVie Tie-Up

In a deal worth more than $800 million, AbbVie injects a vote of confidence into Infinity’s late-stage PI3K inhibitor program, but leaves the biotech the freedom to conduct other partnerships.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC092556

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel